.png)
Chemotherapy-induced nausea and vomiting are serious side effects of cancer treatment that can have a significant negative impact on a patient's quality of life. It is estimated that 70-80% of patients receiving different chemotherapy regimens can experience emesis. Although the prevalence of nausea and vomiting has significantly decreased due to the implementation of new antiemetic drugs, several studies revealed that approximately 30% to 60% of patients still complain of acute or delayed chemotherapy-induced emesis.
Currently, the three categories of drugs with the highest therapeutic index for preventing chemotherapy-induced nausea and vomiting are 5-HT3 receptor antagonists, NK1 receptor antagonists, and glucocorticoids (particularly Dexamethasone). Second-generation 5-HT3 receptor antagonists and NK1 receptor antagonists are more effective due to their prolonged influence but are very expensive and not available in the majority of resource-limited settings. Moreover, NK1 receptor antagonists are not still widely recommended for use in children < 12 years of age.
First-generation 5-HT3 receptor antagonists in combination with Dexamethasone have proven superior activity compared to single agents. It is estimated that slow infusion of the above-mentioned agents can provide long-lasting stable concentrations of drugs in the blood serum contributing to better effect development. It has been shown that Ondansetron continuous infusion has superior efficacy in preventing postsurgical nausea and vomiting.
Therefore, the investigators suggest a continuous infusion of first-generation 5-HT3 receptor antagonists in combination with Dexamethasone as an alternative with potential superior activity.
Sponsor: Immune Oncology Research Institute
Principal Investigator: Julieta Hoveyan, MD,Immune Oncology Research Institute
Study Co-Chair: Ruzanna Papyan, MD,Immune Oncology Research Institute
Study Co-Chair: Samvel Bardakhchyan, MD, PhD,Immune Oncology Research Institute
Study Director: Gevorg Tamamyan, MD, PhD, DSc,Immune Oncology Research Institute
More information can be found at
Study Details | Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone | ClinicalTrials.gov
About IMMONC
Immune Oncology Research Institute (IMMONC) is dedicated to advancing research aimed at preventing, treating, and ultimately curing cancer while making these innovations accessible to those who need them. If you're interested in joining our team, please feel free to contact us at [email protected] or at +374-41 310-048.